 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || midazolam hydrochloride / Generic mfg., S-309309 / Shionogi
Clinical, PK/PD data, Journal: Safety, Tolerability, and Pharmacokinetics of a Novel Anti-obesity Agent, S-309309, in Healthy Adults with or Without Obesity. (Pubmed Central) - Feb 6, 2025
P1
S-309309 did not affect the pharmacokinetics of the cytochrome P450 3A substrate. Overall, S-309309 had an acceptable safety profile and favorable pharmacokinetic and pharmacodynamic characteristics.
- | S-309309 / Shionogi
Journal: Simultaneous Overcoming Approach for Poor Wettability and Low Stability in Stomach by Simple Methods; Formulation Design and Development of Monoacylglycerol Acyltransferase 2 Inhibitor, S-309309. (Pubmed Central) - Oct 21, 2024
In addition, by encapsulating S-309309, the increase of degradation product amount was suppressed under acidic conditions, suggesting that the suppression of degradation product formation would be expected in the stomach after oral dosing. Overall, these results suggest that the drug property issues of S-309309 can be overcome by mixing S-309309 with a water-soluble polymer and encapsulation.
- |||| S-309309 / Shionogi
Trial completion: Safety and Efficacy Study of S-309309 in Obese Adults (clinicaltrials.gov) - Jun 27, 2024
P2, N=365, Completed, Sponsor: Shionogi
Overall, these results suggest that the drug property issues of S-309309 can be overcome by mixing S-309309 with a water-soluble polymer and encapsulation. Active, not recruiting --> Completed
- S-309309 / Shionogi
S-309309, a Novel MGAT2 Inhibitor, Enhances Intestinal Fatty Acid Beta Oxidation and Provides Metabolic Benefits in DIO Mice (Poster Hall (West A4-B2); 1649) - May 20, 2024 - Abstract #ADA2024ADA_2596;
Also, S-309309 improved insulin sensitivity and fatty liver. Taken together, these results suggest that S-309309 may be a promising anti-obesity drug that improves metabolism with multiple mechanisms of action.
- || S-309309 / Shionogi
Trial completion: Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants (clinicaltrials.gov) - Feb 29, 2024
P1, N=14, Completed, Sponsor: Shionogi
Taken together, these results suggest that S-309309 may be a promising anti-obesity drug that improves metabolism with multiple mechanisms of action. Active, not recruiting --> Completed
- || S-309309 / Shionogi
Enrollment closed: Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants (clinicaltrials.gov) - Jan 17, 2024
P1, N=14, Active, not recruiting, Sponsor: Shionogi
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| S-309309 / Shionogi
Enrollment closed: Safety and Efficacy Study of S-309309 in Obese Adults (clinicaltrials.gov) - Oct 31, 2023
P2, N=365, Active, not recruiting, Sponsor: Shionogi
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || S-309309 / Shionogi
Enrollment open: Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants (clinicaltrials.gov) - Oct 31, 2023
P1, N=14, Recruiting, Sponsor: Shionogi
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || S-309309 / Shionogi
New P1 trial: Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants (clinicaltrials.gov) - Oct 29, 2023
P1, N=14, Not yet recruiting, Sponsor: Shionogi
- |||| S-309309 / Shionogi
Enrollment open: Safety and Efficacy Study of S-309309 in Obese Adults (clinicaltrials.gov) - Jul 3, 2023
P2, N=320, Recruiting, Sponsor: Shionogi
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| S-309309 / Shionogi
New P2 trial: Safety and Efficacy Study of S-309309 in Obese Adults (clinicaltrials.gov) - Jun 29, 2023
P2, N=320, Not yet recruiting, Sponsor: Shionogi
- ||| S-309309 / Shionogi
Trial completion: A Study to Assess S-309309 in Healthy and Obese Participants (clinicaltrials.gov) - Nov 7, 2022
P1, N=74, Completed, Sponsor: Shionogi
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| S-309309 / Shionogi
New P1 trial: A Study to Assess S-309309 in Healthy and Obese Participants (clinicaltrials.gov) - Feb 20, 2022
P1, N=86, Recruiting, Sponsor: Shionogi